GeneDx (WGS)
Runs exome and genome testing for pediatric and rare-disease diagnosis.
Something off on this page? Send us feedback.
Provides ExomeDx and GenomeDx testing, interpretation, and related data services for pediatric and rare-disease care. Revenue is concentrated in U.S. diagnostics, with adoption tied to clinician ordering, institutional programs, and third-party reimbursement.
ExomeDx, GenomeDx, and rapid genome offerings anchor a diagnostics business focused on pediatric and rare-disease patients. GeneDx Infinity supports test interpretation, while Fabric Genomics adds software and services for genomic data analysis and biopharma customers.
Sales are concentrated in the United States through clinician referrals, institutional customers, and a field team that works with pediatric specialists, neonatal intensive care units, and late-stage prenatal programs. International revenue is small, though Fabric Genomics adds a broader software channel.
Execution depends on turning complex genome data into clinical answers and expanding use of exome and genome testing. The business also depends on third-party coverage, institutional contracts, and reimbursement rates for tests performed.
Company facts
Unavailable right now.
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 4, 2026 | Canaccord Genuity | Reiterate | Rating: —Target: $75 | Target: $90 |
| Jun 29, 2026 | Guggenheim | Reiterate | Rating: —Target: $70 | Target: $74 |
| Jun 23, 2026 | Piper Sandler | Reiterate | Rating: —Target: $130 | Target: $63 |
| May 5, 2026 | Craig-Hallum | Target | Target: $70 | Target: $85 |
| May 5, 2026 | BTIG | Reiterate | Rating: —Target: $170 | Target: $90 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $132.5M · Total debt $167.4M · Total assets $481.5M · Shareholders' equity $244.2M
- Revenue
- $114.4M
- Operating income
- −$17.5M
- Net income
- −$17.7M
No dividends on record.
| Institutions | 106.49% | 31.76M shares | |
|---|---|---|---|
| 240 holders · as of Jun 30, 2026 | |||
| Insiders | 42.69% | 12.73M shares | |
| 10 holders · as of Sep 18, 2026 | |||
| Strategic holders | 7.28% | 2.17M shares | |
| 1 holder · as of Sep 18, 2024 | |||
| Adds to | 156.46% | ||
29.82M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 156.46%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Keith A. Meister1,2Insiderdirector, 10 percent owner | 17.97% | 5.36M | filed Jun 23, 2026 |
Corvex Management LPInstitution | 16.04% | 4.78M | as of Jun 30, 2026 |
Eli Casdin3Insiderdirector, 10 percent owner | 13.79% | 4.10M | filed Jun 23, 2026 |
Casdin Capital, LLCInstitution | 12.43% | 3.71M | as of Jun 30, 2026 |
School Of Medicine At Mount Sinai Icahn4Insider10 percent owner | 9.12% | 2.72M | filed Nov 19, 2024 |
- Keith A. Meister's transaction reports restate only vehicles that traded; the 2026 ownership statement (5.36M) plus the 3.6K net shares acquired since is used instead.
- Keith A. Meister reports a block also reported by Corvex Management LP; it is counted once, under Corvex Management LP.
- Eli Casdin's transaction reports restate only vehicles that traded; the 2025 ownership statement (4.10M) plus the 16.5K net shares acquired since is used instead.
- Reported at 4.89% on Feb 21, 2025, under the 5% line, so no further filing is required.
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 16, 2026 | Katherine Stueland | director, officer: CHIEF EXECUTIVE OFFICER | −10,501 | $97.61 |
| Sep 16, 2026 | Kevin Feeley | officer: CHIEF FINANCIAL OFFICER | −3,728 | $97.61 |
| Sep 9, 2026 | Kevin Feeley | officer: CHIEF FINANCIAL OFFICER | −1,285 | $84.22 |
| Sep 9, 2026 | Katherine Stueland | director, officer: CHIEF EXECUTIVE OFFICER | −3,692 | $84.22 |
| Sep 1, 2026 | Kevin Feeley | officer: CHIEF FINANCIAL OFFICER | −372 | $83.84 |
Unavailable right now.